T-cell gene therapy for low mutational burden cancer

Abstract

T-cell gene therapy is a relatively new immunotherapeutic strategy to treat cancer. Where immune checkpoint inhibition demonstrates promising results in cancer with a high mutational burden, cancers with a low mutational burden respond less well. For these cancers, T-cell gene therapy might be an attractive alternative. In this thesis, uveal melanoma and synovial sarcoma are described as favorable targets for T-cell gene therapy targeting PRAME. Furthermore, the immune tumor microenvironment of synovial sarcoma is studied in depth.